Timo Ilmari Vaara
Fondateur chez Northern Antibiotics Oy
Profil
Timo Ilmari Vaara is the founder and currently serves as the Chairman of Northern Antibiotics Oy, a company founded in 2003.
He has also held former positions as the Chief Executive Officer of UniCrop Oy and Lymphatix Oy, as well as the Principal of Alko Oy.
Mr. Vaara obtained his graduate degree from the University of Helsinki in 1984.
Postes actifs de Timo Ilmari Vaara
| Sociétés | Poste | Début |
|---|---|---|
Northern Antibiotics Oy
 Northern Antibiotics Oy Pharmaceuticals: MajorHealth Technology Northern Antibiotics Oy engages in the discovery and development of novel antibiotics against multidrug-resistant gram-negative bacteria. It develops compounds, which are active against difficult-to-treat gram-negative bacteria, such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. The company was founded by Martti Sakari Vaara and Timo Ilmari Vaara in 2003 and is headquartered in Helsinki, Finland. | Fondateur | 14/04/2010 |
Anciens postes connus de Timo Ilmari Vaara
| Sociétés | Poste | Fin |
|---|---|---|
UniCrop Oy
 UniCrop Oy Pharmaceuticals: MajorHealth Technology UniCrop Oy develops sprouting technology for the production of therapeutic proteins. It develops prouting technology for the production of therapeutic proteins. It uses molecular biology technologies to develop new uses for plants. The company was founded by Kimmo Koivu and Viktor Kuvshinov in 1998 and is located in Helsinki, Finland. | President | - |
Alko Oy
 Alko Oy Specialty StoresRetail Trade Alko Oy retails alcoholic beverages. Its products include wines, spirits, beers, ciders, long drinks, and non-alcoholic beverages. The company also offers packaging materials, bottle openers, bar accessories, glasses, gift deliveries, and gift cards. Alko was founded on April 5, 1932 and is headquartered in Helsinki, Finland. | Corporate Officer/Principal | - |
Lymphatix Oy
 Lymphatix Oy Miscellaneous Commercial ServicesCommercial Services Part of Premier Veterinary Group Plc, Lymphatix Oy is a Finnish company that researches and develops therapies for vascular and circulatory system-related diseases and cancer. The company is based in Helsinki, Finland. Lymphatix was acquired by Ark Therapeutics Group Plc on January 08, 2008 for $3.31 million. | President | - |
Formation de Timo Ilmari Vaara
| University of Helsinki | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Alko Oy
Alko Oy Specialty StoresRetail Trade Alko Oy retails alcoholic beverages. Its products include wines, spirits, beers, ciders, long drinks, and non-alcoholic beverages. The company also offers packaging materials, bottle openers, bar accessories, glasses, gift deliveries, and gift cards. Alko was founded on April 5, 1932 and is headquartered in Helsinki, Finland. | Retail Trade |
UniCrop Oy
UniCrop Oy Pharmaceuticals: MajorHealth Technology UniCrop Oy develops sprouting technology for the production of therapeutic proteins. It develops prouting technology for the production of therapeutic proteins. It uses molecular biology technologies to develop new uses for plants. The company was founded by Kimmo Koivu and Viktor Kuvshinov in 1998 and is located in Helsinki, Finland. | Health Technology |
Lymphatix Oy
Lymphatix Oy Miscellaneous Commercial ServicesCommercial Services Part of Premier Veterinary Group Plc, Lymphatix Oy is a Finnish company that researches and develops therapies for vascular and circulatory system-related diseases and cancer. The company is based in Helsinki, Finland. Lymphatix was acquired by Ark Therapeutics Group Plc on January 08, 2008 for $3.31 million. | Commercial Services |
Northern Antibiotics Oy
Northern Antibiotics Oy Pharmaceuticals: MajorHealth Technology Northern Antibiotics Oy engages in the discovery and development of novel antibiotics against multidrug-resistant gram-negative bacteria. It develops compounds, which are active against difficult-to-treat gram-negative bacteria, such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. The company was founded by Martti Sakari Vaara and Timo Ilmari Vaara in 2003 and is headquartered in Helsinki, Finland. | Health Technology |
